Abbreviations: 3D, 3 direct-acting antiviral; DSV, dasabuvir; LLOD, lower limit of detection; LLOQ, lower limit of quantification; OBV, ombitasvir; PTV/r, paritparevir codosed with ritonavir; SVR, sustained virologic response. 
While the development of first-generation protease inhibitors such as boceprevir and telaprevir in combination with pegylated IFN (pegIFN) and ribavirin (RBV) increased SVR rates relative to standalone treatment with pegIFN/RBV, negative predictors of SVR including cirrhosis and prior treatment experience with pegIFN/RBV remained relevant 3, 4 .
Historically, an integral goal of patient management and an important on-treatment predictor of SVR has been the achievement of a rapid virologic response (RVR; defined as undetectable HCV RNA at treatment week 4) 5 . While the addition of boceprevir to pegIFN/ RBV increased overall SVR rates, early viral kinetics remained a predictor of response 6 . Indeed, a Response Guided Therapy (RGT) study of pegIFN/RBV plus telaprevir demonstrated that, based on the regimen's ability to induce RVR, treatment of 24 weeks was noninferior to 48 weeks of treatment, which resulted in shorter treatment durations for two-thirds of patients 7 . Newer antiviral agents such as sofosbuvir (SOF) and simeprevir combined with pegIFN/RBV increased the proportion of patients achieving RVR and improved overall outcomes; however, an unfavourable IL28B genotype and advanced fibrosis remained predictors of lower SVR rates 8, 9 . Little 
| MATERIALS AND METHODS

| Overall study design
The objectives of this analysis were to 1) determine the association between time to viral suppression and achievement of SVR12
(HCV RNA <LLOQ, 12 weeks after the last dose of treatment) and 2) explore the association between baseline characteristics and time to viral suppression in HCV GT1-infected patients. We conducted a pooled analysis of all patients with HCV GT1 infection with or without cirrhosis who had received 3D ± RBV during six phase 3 clinical trials:
and TURQUOISE-II 13 Detailed study design information has been described previously [6] [7] [8] [9] [10] . Briefly, all six trials were randomized; PEARL-II   and TURQUOISE-II were open-label studies; the PEARL-III and   PEARL-IV studies were double-blinded, and the 
| Patients
Patients 18-70 years of age were eligible to enroll in one of the six Patients were excluded if they had a positive test result for hepatitis B surface antigen or anti-HIV antibodies during screening. In the TURQUOISE-II study, patients were excluded if serum albumin levels were <2.8 g/dL or if platelet count was <60 x 10 9 /L; for all other trials, patients were excluded if albumin was below the lower limit of normal (LLN) or if platelet count was <120 × 10 9 /L.
| Efficacy assessments
HCV RNA was measured using the Roche COBAS TaqMan 
| Statistical analyses
The association between time of first suppression <LLOQ or <LLOD and subsequent achievement of SVR was analysed using the CochranArmitage trend test. Time to suppression was compared between subgroups of demographic characteristics or clinical characteristics using a log-rank test in univariate analyses. Patients with non-virologic failure (eg, loss to follow-up, premature treatment discontinuation) were excluded from these analyses. Analysis of covariance was used to determine characteristics that were jointly associated with time to suppression. SAS software for the UNIX operating system (SAS Institute) was used for all analyses. All statistical tests were two-sided, with a significance level of 0.05.
| RESULTS
| Patients
A total of 2053 patients received at least one dose of study drug in the six phase 3 trials. Demographic and baseline characteristics are summarized in Table 1 . Twenty-six patients had non-virologic failure and were excluded from the analysis; time to suppression <LLOQ and <LLOD and subsequent achievement of SVR12 were evaluated in the resulting 2027 patients.
| TIME TO SUPPRESSION AND SVR12 RATE
The cumulative proportions of subjects with initial HCV RNA suppression <LLOQ at weeks 1, 2, 4 and 6 were 31%, 81%, 99% and 100%, respectively. Achievement of SVR12 was not affected by the time to viral suppression <LLOQ (P=.42, Figure 1A ) or time to viral suppression <LLOD (P=.64, Figure 1B) . The absence of a relationship between time to suppression and SVR12 was not affected by the presence of cirrhosis ( Figure 1C ).
| ASSOCIATION BETWEEN TIME TO SUPPRESSION AND BASELINE CHARACTERISTICS
Univariate analyses were conducted to evaluate which, if any, base- Table 2) .
T Among patients with cirrhosis, the increase in time to viral suppression may be due to the myriad effects of cirrhosis on antiviral activity.
For example, drug delivery may be reduced by either portosystemic shunting or altered intrahepatic microcirculation as a consequence of increased collagen and intracellular matrix 16 . Cirrhosis may also be associated with significant immune dysfunction that could impede viral suppression 17 . In older patients, the delay in viral suppression may be attributable to a reduction in liver blood flow or blunted adaptive response Response to DAA treatment is measured by plasma HCV RNA levels, which are a surrogate for viral decline in the liver, and compartmental differences may exist. Plasma HCV RNA levels early after treatment initiation (0-4 days) have been shown to be lower than in the liver, which is the primary site for viral replication 19 . Therefore, it is possible that for the 81% of patients that achieved HCV RNA <LLOQ by week 2, the observed viral suppression may not correspond to the decline in viral replication in the liver necessary to achieve SVR12
19
. Conversely, even if plasma viral decline does correlate closely with intrahepatic decline, it is still possible that durations of therapy that extend for many weeks beyond the time of initial plasma clearance result in higher SVR12 rates, as slower responders are able to reach SVR12, which they may not have achieved with shorter treatment durations.
As immune function can play a role in initial viral suppression, it is likely that a comprehensive immune response also plays a significant role in achievement of SVR12. However, it is difficult to both measure and quantify the magnitude of these effects. the SODAPI study. One limitation of our study is the lack of treatment durations shorter than 12 weeks. We cannot exclude the possibility that early viral kinetics may identify patients in whom further shortening of treatment is possible.
In conclusion, we show that early virologic suppression of HCV RNA is nearly universal by week 4 following treatment with OBV/PTV/r + DSV, with or without RBV. Unlike previous findings evaluating the viral kinetics of IFN-containing regimens
21
, time to initial suppression following treatment with 3D ± RBV was not related to subsequent achievement of SVR12, suggesting that monitoring of HCV RNA levels at week 4 may not be useful for clinical decision-making regarding treatment duration and that on-treatment virologic monitoring could be eliminated. As RBV use is part of the treatment guidelines for GT1a, monitoring for safety and adherence is still recommended. The interferon-free 3D regimen of OBV/PTV/r + DSV appears sufficiently potent to achieve both rapid and sustainable viral suppression, which may permit treatment durations shorter than 12 weeks in select patient populations.
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